Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies

(Reuters) - Doctors have struggled for years to deliver medication effectively to the inner ear, but two companies are vying to be first to introduce new treatments which, if successful, could together chalk up some $800 million in peak sales.